DZUNG NGUYEN: Open Payments
NPI 1285108944 · WESTMINSTER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$522 in 20 payments from 9 companies in 2025. Trend: 2023 $96 · 2024 $401 · 2025 $522
Food & beverage: $522
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 7 | $180 |
| Madrigal Pharmaceuticals | 4 | $154 |
| Amgen Inc. | 2 | $39 |
| Merck Sharp & Dohme LLC | 2 | $34 |
| Novartis Pharmaceuticals Corporation | 1 | $33 |
| Dexcom, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
Products named: REZDIFFRA, Briviact, Nayzilam, OTEZLA, GARDASIL 9, LEQVIO, Dexcom G6 Transmitter, ImmunoCAP.
Industry payments across CA — which companies pay providers there.
